TargetBeta
CD33
CD33 molecule · also SIGLEC3, SIGLEC-3, p67, FLJ00391 · CD molecules
1 program in company-led studies act on CD33, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-CD33 Antibody-drug Conjugate BL-M11D1 | Sichuan Biokin Pharmaceutical | – | phase 3 | 43 running | – | the company's pipeline |
Conditions their studies are in
- Leukemia, Myeloid, Acute, 1 program
- Myelodysplastic Syndromes, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Anti-CD33 Antibody-drug Conjugate BL-M11D1 · Sichuan Biokin Pharmaceutical · phase 3 · NCT05924750
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.